Skip to menu Skip to content Skip to footer
Associate Professor Peter Mollee
Associate Professor

Peter Mollee

Email: 

Overview

Background

Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.

Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.

Availability

Associate Professor Peter Mollee is:
Available for supervision

Qualifications

  • Masters (Coursework) of Medical Science, University of Newcastle
  • Royal Australasian College of Physicians, Royal Australasian College of Physicians
  • Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia

Research impacts

The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.

Works

Search Professor Peter Mollee’s works on UQ eSpace

326 works between 1997 and 2025

281 - 300 of 326 works

2006

Journal Article

Hereditary fibrinogen A alpha-chain amyloidosis

Lane, S. W., Goodman, H. J., Francis, L., Bofinger, A. M. and Mollee, P. N. (2006). Hereditary fibrinogen A alpha-chain amyloidosis. Pathology, 38 (4), 380-382. doi: 10.1080/00313020600820823

Hereditary fibrinogen A alpha-chain amyloidosis

2006

Journal Article

Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma

Gandhi, M. K., Lambley, E., Burrows, J., Dua, U., Elliott, S., Shaw, P. J., Prince, H. M., Wolf, M., Clarke, K., Underhill, C., Mills, T., Mollee, P., Gill, D., Marlton, P., Seymour, J. F. and Khanna, R. (2006). Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clinical Cancer Research, 12 (2), 460-464. doi: 10.1158/1078-0432.CCR-05-2008

Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma

2006

Conference Publication

Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseases

Tate, J.R., Mollee, P., Carter, A. and Gill, D. (2006). Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseases. 58th Annual Meeting of the American Association of Clinical Chemistry, Chicago, IL, United States, 23-27 July 2006. Washington, DC, United States: American Association for Clinical Chemistry.

Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseases

2006

Conference Publication

Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).

Lane, SW, Saal, R, Negus, S, Mollee, P, Mather, M, Gill, D, Mills, AK, Bird, RJ, Hourigan, MJ, Jones, M and Marlton, P (2006). Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).. 48th Annual Meeting of the American-Society-of-Hematology, Orlando Fl, Dec 09-12, 2006. WASHINGTON: AMER SOC HEMATOLOGY.

Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML).

2006

Journal Article

Effects of hyperlipidemia on plasma sodium, potassium, and chloride measurements by an indirect ion-selective electrode measuring system

Dimeski, Goce, Mollee, Peter and Carter, Andrew (2006). Effects of hyperlipidemia on plasma sodium, potassium, and chloride measurements by an indirect ion-selective electrode measuring system. Clinical Chemistry, 52 (1), 155-156. doi: 10.1373/clinchem.2005.054981

Effects of hyperlipidemia on plasma sodium, potassium, and chloride measurements by an indirect ion-selective electrode measuring system

2005

Journal Article

Increased Lipid Concentration Is Associated with Increased Hemolysis

Dimeski, Goce, Mollee, Peter and Carter, Andrew (2005). Increased Lipid Concentration Is Associated with Increased Hemolysis. Clinical Chemistry, 51 (12), 2425-2425. doi: 10.1373/clinchem.2005.058644

Increased Lipid Concentration Is Associated with Increased Hemolysis

2005

Conference Publication

Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL)

Lane, Steven W., Mollee, Peter N., Bird, Robert, Porceddu, Sandro and Gill, Devinder (2005). Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL). 47th ASH Annual Meeting, Atlanta, GA United States, 10-13 December 2005. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v106.11.4993.4993

Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL)

2005

Conference Publication

Falsely low serum free light chain concentration in patients with monoclonal light chain diseases

Mollee, Peter, Tate, Jill, Dimeski, Goce and Gill, Devinder (2005). Falsely low serum free light chain concentration in patients with monoclonal light chain diseases. 47th ASH Annual Meeting, Atlanta, GA United States, 10-13 December 2005. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v106.11.5077.5077

Falsely low serum free light chain concentration in patients with monoclonal light chain diseases

2005

Journal Article

Role of VAD in the initial treatment of multiple myeloma

Lane, Steven W., Gill, Devinder, Mollee, Peter N. and Rajkumar, S. Vincent (2005). Role of VAD in the initial treatment of multiple myeloma. Blood, 106 (10), 3674-3675. doi: 10.1182/blood-2005-07-2610

Role of VAD in the initial treatment of multiple myeloma

2005

Journal Article

The reporting of serum protein electrophoresis to clinicians

Tate, Jillian R., Mollee, Peter and Gill, Devinder (2005). The reporting of serum protein electrophoresis to clinicians. Clinica Chimica Acta, 358 (1-2), 204-205. doi: 10.1016/j.cccn.2005.04.010

The reporting of serum protein electrophoresis to clinicians

2005

Journal Article

Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission

Song, Kevin W., Mollee, Peter N., Hogge, Donna E., Gupta, Vikas, Bernett, Michael J., Forrest, Donna L., Lavoie, Julye C., Nevill, Thmas J., Nantel, Stephen H., Shepherd, John D., Smith, Clay A., Sutherland, Heather J., Toze, Cynthia L., Crump, Michael and Keating, Armand (2005). Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leukemia and Lymphoma, 46 (4), 525-531. doi: 10.1080/10428190400025112

Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission

2005

Journal Article

Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?

Rifkind, Joshua, Mollee, Peter, Messner, Hans and Lipton, Jeffrey (2005). Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?. Leukemia & Lymphoma, 46 (2), 217-223. doi: 10.1080/10428190400015022

Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?

2005

Journal Article

Serum free light chains for monitoring multiple myeloma

Tate, J., Mollee, P. and Gill, D. (2005). Serum free light chains for monitoring multiple myeloma. British Journal of Haematology, 128 (3), 405-406. doi: 10.1111/j.1365-2141.2004.05338.x

Serum free light chains for monitoring multiple myeloma

2005

Conference Publication

Falsely low serum free light chain concentration in patients with monoclonal light chain diseases

Mollee, Peter, Tate, Jill, Dimeski, Goce and Gill, Devinder (2005). Falsely low serum free light chain concentration in patients with monoclonal light chain diseases. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology.

Falsely low serum free light chain concentration in patients with monoclonal light chain diseases

2005

Conference Publication

Accelerated delivery of Rituximab is safe on an out-patient basis.

Middleton, HJ, Mollee, P, Bird, R, Mills, AK, Marlton, P and Gill, D (2005). Accelerated delivery of Rituximab is safe on an out-patient basis.. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta Ga, Dec 10-13, 2005. WASHINGTON: AMER SOC HEMATOLOGY.

Accelerated delivery of Rituximab is safe on an out-patient basis.

2005

Journal Article

Stem cell transplantation for mantle cell lymphoma: if, when and how?

Kiss, T. L., Mollee, P., Lazarus, H. M. and Lipton, J. H. (2005). Stem cell transplantation for mantle cell lymphoma: if, when and how?. Bone Marrow Transplantation, 36 (8), 655-661. doi: 10.1038/sj.bmt.1705080

Stem cell transplantation for mantle cell lymphoma: if, when and how?

2005

Conference Publication

Falsely low serum free light chain concentration in patients with monoclonal light chain diseases

Tate, J.R., Mollee, P., Dimeski, G. and Gill, D. (2005). Falsely low serum free light chain concentration in patients with monoclonal light chain diseases. Annual Meeting of the American Association Clinical Chemistry, Orlando, FL, United States, 24-28 July 2005. Washington, DC, United States: American Association for Clinical Chemistry.

Falsely low serum free light chain concentration in patients with monoclonal light chain diseases

2005

Conference Publication

A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma

Kuruvilla, J., Mollee, P., Song, K., Zaretsky, Y., Panzarella, T., McCrae, J., Nagy, T., Crump, M. and Keating, A. (2005). A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 9 -11 June 2005. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/annonc/mdi582

A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma

2005

Conference Publication

Pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) with hyper-CVAD chemotherapy regimen for aggressive lymphoid malignancy.

Lane, SW, Crawford, J, Kenealy, M, Cull, G, Seymour, JF, Prince, M, Marlton, P, Gill, D and Mollee, PN (2005). Pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) with hyper-CVAD chemotherapy regimen for aggressive lymphoid malignancy.. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V106.11.4274.4274

Pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) with hyper-CVAD chemotherapy regimen for aggressive lymphoid malignancy.

2005

Conference Publication

Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL)

Lane, S. W., Mollee, P. N., Bird, R., Porceddu, S. and Gill, D. (2005). Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL). 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology.

Aggressive cutaneous squamous cell carcinoma (SCC) in chronic lymphocytic leukaemia (CLL)

Funding

Current funding

  • 2018 - 2025
    An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies
    NHMRC MRFF - Lifting Clinical Trials Registries Capacity
    Open grant

Past funding

  • 2022 - 2023
    Laser capture microdissection to empower cancer discoveries, improve diagnosis, treatment and outcomes in amyloidosis patients
    IPF Healthy - Medical Research
    Open grant
  • 2019 - 2023
    Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma - the FRAIL-M study (MRFF LSCD Grant Administered by Monash)
    Monash University
    Open grant
  • 2017 - 2021
    Benefit of 2D-strain surveillance in improving cardiovascular outcomes in cancer patients undergoing cardiotoxic chemotherapy
    Baker IDI Heart & Diabetes Institute
    Open grant
  • 2013 - 2020
    The Diamantina Individualised Oncology Care Centre (DIOCC)
    Australian Cancer Research Foundation
    Open grant
  • 2007
    Valproic acid and cytarabine therapy for elderly or relapsed acute myeloid leukaemia
    Leukaemia Foundation
    Open grant

Supervision

Availability

Associate Professor Peter Mollee is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Media

Enquiries

For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au